Bank of Nova Scotia
BHVN

Bank of Nova Scotia’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bank of Nova Scotia’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,364
Closed -$811K – 1306
2022
Q3 		$811K Buy
5,364
+487
+10% +$72.2K ﹤0.01% 844
2022
Q2 		$711K Sell
4,877
-422
-8% -$53.9K ﹤0.01% 928
2022
Q1 		$628K Sell
5,299
-2,676
-34% -$334K ﹤0.01% 1008
2021
Q4 		$1.11M Buy
+7,975
New +$1.01M ﹤0.01% 969

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Bank of Nova Scotia's BHVN Position: Q4 2022 in Review

Bank of Nova Scotia sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 5,364 shares — an estimated $811K sold.

Bank of Nova Scotia first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $1.11M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Bank of Nova Scotia reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Bank of Nova Scotia sold 5,364 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $811K.
  • Bank of Nova Scotia first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • Bank of Nova Scotia's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.11M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Bank of Nova Scotia's 13F filing for Q4 2022, filed 9 Feb 2023.